因卡膦酸二钠对小细胞肺癌导致的溶骨性骨转移的治疗效果  

Therapeutic effect of inkadronate disodium on osteolytic bone metastases due to small cell lung cancer

作　　者：张米娜[1] 王慧娟[1] ZHANG Mi-na;WANG-Hui-juan(Department of Respiratory Medicine,Henan Cancer Hospital,Zhengzhou,450003,China)

机构地区：[1]河南省肿瘤医院呼吸内科,450003

出　　处：《中国实用医药》2021年第26期11-14,共4页China Practical Medicine

摘　　要：目的分析小细胞肺癌导致的溶骨性骨转移采用因卡膦酸二钠的治疗效果。方法45例小细胞肺癌导致的溶骨性骨转移患者作为研究对象,依据随机数字排列表法将其分成对照组(22例)及实验组(23例)。对照组患者使用唑来膦酸治疗,实验组患者使用因卡膦酸二钠治疗。比较两组患者治疗前后的视觉模拟评分法(VAS)评分及骨密度,活动能力改善情况,不良反应发生情况。结果治疗后,实验组患者的VAS评分为(2.99±0.37)分、对照组患者的VAS评分为(3.29±0.76)分,均低于本组治疗前的(7.53±1.82)、(7.56±1.89)分,差异具有统计学意义(P<0.05)。治疗前后两组患者的VAS评分组间比较,差异无统计学意义(P>0.05)。治疗前后,两组患者的骨密度组间、组内比较,差异均无统计学意义(P>0.05)。两组患者的活动能力改善有效率比较,差异无统计学意义(P>0.05)。实验组患者的不良反应发生率4.35%低于对照组的27.27%,差异具有统计学意义(P<0.05)。结论小细胞肺癌导致的溶骨性骨转移患者使用因卡膦酸二钠治疗,能在一定程度上改善骨痛,恢复机体活动能力,发挥较好的临床干预效果,且不良反应发生率低,患者耐受良好。Objective To analyze the therapeutic effect of inkadronate disodium on osteolytic bone metastases due to small cell lung cancer.Methods A total of 45 patients with osteolytic bone metastases due to small cell lung cancer as study subjects were divided into control group(22 cases)and experimental group(23 cases)according to random numerical table.Patients in the control group were treated with zoledronic acid,and patients in the experimental group were treated with inkadronate disodium.The visual analogue scale(VAS)score and bone density before and after treatment,improvement of mobility,and occurrence of adverse reactions of the two groups were compared.Results After treatment,VAS scores of patients in the experimental group were(2.99±0.37)points and those in the control group were(3.29±0.76)points,which were lower than(7.53±1.82)and(7.56±1.89)points before treatment in this group,and the differences were statistically significant(P<0.05).Before and after treatment,there was no statistically significant difference in the VAS scores between the two groups(P>0.05).Before and after treatment,there was no statistically significant difference in bone mineral density between and within the two groups(P>0.05).The difference was not statistically significant when comparing the efficiency of improvement in mobility between the two groups(P>0.05).The incidence of adverse reactions 4.35%in the experimental group was lower than 27.27%of the control group,and the difference was statistically significant(P<0.05).Conclusion For patients with osteolytic bone metastases caused by small cell lung cancer,inkadronate disodium can improve bone pain and restore the body’s mobility to a certain extent,and play a better clinical intervention effect with low incidence of adverse effects and good patient tolerance.

关 键 词：溶骨性骨转移 小细胞肺癌 因卡膦酸二钠 疼痛 骨密度 

分 类 号：R734.2[医药卫生—肿瘤]